Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportPreclinical Probes for Oncology

Visualizing cytokeratin-14 levels in basal-like breast cancer via immunoSPECT imaging

Hao Ji, Xiao Zhang, Yongkang Gai and Xiaoli Lan
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 2873;
Hao Ji
1Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Key Laboratory of Molecular Imaging.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiao Zhang
2Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongkang Gai
3Wuhan Union Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoli Lan
3Wuhan Union Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

2873

Introduction: Basal-like breast cancer (BLBC) is an invasive subtype of breast cancer with a worse prognosis and unique morphological characteristics. Lack of specific biomarkers makes it extremely difficult for accurate diagnosis in the early stage and specific targeted therapy. Consequently, it is particularly important to find specific biomarkers. Cytokeratin-14 (CK14), also known as keratin 14, is mainly expressed in the basal layer of stratified squamous epithelium. It has a critical role in maintaining cell morphology and resisting external mechanical stress. High levels of CK14 have been found in multiple types of tumors, especially in BLBC. In our study, an anti-CK14 monoclonal antibody was successfully produced, purified, and labeled with 99mTc to evaluate the feasibility of visualizing the CK14 level in BLBC.

Methods: The anti-CK14 monoclonal antibody was generated through hybridoma technology and conjugated with succinimidyl 6-hydraziniumnicotinate hydrochloride. The radiolabeling efficiency and the stability of 99mTc-HYNIC-Anti-CK14mAb were determined using instant thin layer chromatography. MDA-MB-468 and MDA-MB-231 cells were selected. The in vitro binding specificity of the tracer to CK14 was validated by immunofluorescence, cell uptake and internalization experiments. Single-photon emission computed tomography (SPECT) scan was performed in tumor-bearing nude mice at 6h, 12h, 24h. Biodistribution study were consistent with SPECT imaging, and the tumor/muscle (T/M) and tumor/blood (T/B) ratio were calculated.

Results: Anti-CK14mAb was successfully prepared. The radiolabeling yield of 99mTc-HYNIC-Anti-CK14mAb reached 73.58 ± 5.35% (n=3) with specific radioactivity at 528.36 MBq/nmol. Higher CK14 levels were found in MDA-MB-468 cells and tumors when compared with that of MDA-MB-231 cells and tumors as revealed by western blotting and immunohistochemistry. Cell uptake experiments demonstrated a rising trend with time in MDA-MB-468 cells. The uptake ratio increased from 0.535% ± 0.053% (1 h) to 1.568% ± 0.247% (6 h). In contrast, the uptake rate in the blocking group cells was much lower (0.441%–0.557%) at 6 h. These results verified the specific binding of 99mTc-HYNIC-Anti-CK14mAb to CK14+ MDA-MB-468 cells. Internalization assays indicated the tendency of internalization ratio of MDA-MB-468 cells was similar to the tendency of total cell uptake ratio. The ratio of internalization to total cell uptake (internalization + membrane bound) increased from 51.39% ± 3.51% at 1 h to 76.39% ± 3.65% at 6 h. These results were consistent with the fact that CK14 was mainly distributed inside the cells. On the SPECT images, higher radioactivity accumulation was observed in MDA-MB-468 tumors than in MDA-MB-231 tumors, at 6h, 12h, 24h post injection of the tracer. Biodistribution study demonstrated the radioactivity accumulation in MDA-MB-468 tumors (14.245 ± 3.410 %ID/g) was significantly higher than that of MDA-MB-231 tumors (6.585 ± 0.586 %ID/g) and blocking group (injected with 100 times excess antibodies, 7.361 ± 0.657 %ID/g). Moreover, the tumor to blood ratios (T/M 18.18 ± 7.613 vs 6.352 ± 1.347 vs 7.980 ± 2.038) and tumor to blood ratios (T/B 1.702 ± 0.613 vs 0.611 ± 0.085 vs 0.6797 ± 0.1637) of the MDA-MB-468 group were significantly higher than that of the blocking group and MDA-MB-231 control group, demonstrating the good affinity and specificity of 99mTc-HYNIC-Anti-CK14mAb for targeting BLBC tumor.

Conclusions: We developed a molecular probe 99mTc-HYNIC-Anti-CK14mab targeting CK14 with high affinity and specificity to MDA-MB-468 tumors, making it a potential imaging tool for the diagnosis of CK14 overexpressing BLBC. In the future, the developed tracer may also provide valuable information to help determine which patients are suitable for anti-CK14 therapy.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Visualizing cytokeratin-14 levels in basal-like breast cancer via immunoSPECT imaging
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Visualizing cytokeratin-14 levels in basal-like breast cancer via immunoSPECT imaging
Hao Ji, Xiao Zhang, Yongkang Gai, Xiaoli Lan
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 2873;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Visualizing cytokeratin-14 levels in basal-like breast cancer via immunoSPECT imaging
Hao Ji, Xiao Zhang, Yongkang Gai, Xiaoli Lan
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 2873;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • In-vitro stability and labelling yield of 188Re-N-DEDC lipiodol using indigenously produced freeze-dried kits in trans-arterial radionuclide therapy (TART) for treatment of hepatocellular carcinoma (HCC)
  • Biodistribution and in-vivo stability of a pet tracer for lung perfusion imaging
  • Development and initial evaluation of a fully human anti-nectin-4 antibody as theranostic probes for nectin-4 positive triple negative breast cancers
Show more Preclinical Probes for Oncology

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire